Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ENTA closed down 2.08 percent on Wednesday, November 14, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 19
|See historical ENTA trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 14||20 DMA Resistance||Bearish||0.00%|
|Nov 14||NR7||Range Contraction||0.00%|
|Nov 13||20 DMA Resistance||Bearish||-2.08%|
|Nov 12||20 DMA Resistance||Bearish||-1.77%|
|Nov 12||Outside Day||Range Expansion||-1.77%|
|Nov 9||Fell Below 20 DMA||Bearish||-0.84%|
|Nov 9||New Downtrend||Bearish||-0.84%|
|Nov 9||NR7||Range Contraction||-0.84%|
|Nov 8||Fell Below 50 DMA||Bearish||-3.63%|
|Nov 8||20 DMA Support||Bullish||-3.63%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ENTA news...
|52 Week High||127.77|
|52 Week Low||44.52|
|200-Day Moving Average||92.7646|
|50-Day Moving Average||81.9846|
|20-Day Moving Average||77.484|
|10-Day Moving Average||78.863|
|Average True Range||4.2014|
|Chandelier Exit (Long, 3 ATRs )||73.7158|
|Chandelier Exit (Short, 3 ATRs )||82.9942|
|Upper Bollinger Band||83.3043|
|Lower Bollinger Band||71.6637|
|Percent B (%b)||0.32|
|MACD Signal Line||-1.2555|
|Market Cap||1.44 Billion|
|Num Shares||19.1 Million|
|Price-to-Earnings (P/E) Ratio||-69.79|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||79.45|
|Resistance 3 (R3)||79.79||78.76||78.77|
|Resistance 2 (R2)||78.76||77.72||78.60||78.54|
|Resistance 1 (R1)||77.07||77.08||76.56||76.73||78.32|
|Support 1 (S1)||74.35||75.00||73.84||74.01||72.42|
|Support 2 (S2)||73.32||74.36||73.16||72.20|
|Support 3 (S3)||71.63||73.32||71.97|
|Support 4 (S4)||71.29|